argenx Just Dropped $2.2 Billion on a Company Most People Haven't Heard Of
argenx is spending $2.2 billion in cash to buy Forte Biosciences and its early-stage anti-CD122 antibody, FB102. It's the biggest bet yet in the company's push to become more than a one-drug wonder.
The Biggest Bet argenx Has Ever Made
When your flagship drug prints $4.2 billion in annual sales, you have options. You can sit back, ride the wave, and squeeze every last dollar out of your hit product. Or you can take $2.2 billion in cash, walk up to a small clinical-stage company most investors barely know, and buy the whole thing.
argenx chose door number two.
The Dutch immunology company announced it will acquire Forte Biosciences for $77 per share in cash, a deal worth roughly $2.2 billion. It's structured as a tender offer (argenx offers to buy shares directly from Forte shareholders) followed by a back-end merger for any holdouts. No financing contingency, no complicated stock swaps. Just cash from the balance sheet. The companies expect to close this quarter.
The price tag represents about an 86% premium over Forte's average trading price since its vitiligo data dropped in July, though some reports peg the premium closer to 40% versus the most recent closing price. Either way, argenx is paying up.
But for what, exactly?
Meet FB102, the Drug argenx Is Really Buying
Forte Biosciences isn't a household name, even in biotech circles. The company went public back in 2020 through a reverse merger with Tocagen, and its earlier lead program (FB-401 for inflammatory skin disease) flopped in a Phase 2 trial in 2021. Not exactly a glamorous origin story.
But Forte pivoted hard, and its new lead asset is FB102: an antibody that blocks a protein called CD122. Think of CD122 as a shared doorbell for two inflammatory signals (IL-2 and IL-15) that activate certain immune cells. By blocking that doorbell, FB102 dials down the aggressive immune cells that cause autoimmune damage.
The clever part? FB102 is designed to leave regulatory T cells (the immune system's peacekeepers) relatively untouched. Most immunosuppressive drugs are like using a sledgehammer on your entire immune system. FB102 is more like selectively unplugging the troublemakers while letting the hall monitors keep doing their jobs.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Forte has early clinical data in two conditions: vitiligo (positive Phase 1b results reported in July 2026) and celiac disease (positive Phase 1b data showing improvements in tissue samples, T-cell markers, and gluten-related symptoms versus placebo). A Phase 2 celiac study is underway, with data expected in 2026.
The company is also eyeing alopecia areata, which means FB102 could potentially address a whole menu of autoimmune conditions. Leerink analyst Thomas Smith called it a "pipeline-in-a-product" opportunity, and that framing helps explain why argenx was willing to write such a big check.
Why argenx Can't Afford to Be a One-Trick Pony
Let's talk about VYVGART, because understanding this deal requires understanding what argenx already has.
VYVGART (efgartigimod) works by blocking the FcRn receptor, which recycles antibodies in the body. By blocking FcRn, VYVGART causes harmful antibodies to get cleared faster. It's approved for generalized myasthenia gravis and CIDP (chronic inflammatory demyelinating polyneuropathy), and the franchise has been on a tear.
Global sales hit $4.2 billion in 2025, up 90% from the prior year. Q1 2026 came in around $1.3 billion, marking the 17th consecutive quarter of growth. The company has treated roughly 19,000 patients worldwide. By any measure, VYVGART is a blockbuster.
But argenx's leadership knows what happens to companies that depend on a single drug platform. Patents expire. Competitors emerge. Growth eventually plateaus. That's why the company laid out its "Vision 2030" strategy: 10 labeled indications, five Phase 3 molecules, and 50,000 patients treated globally.
Internally, argenx advanced four new pipeline molecules in 2025 and expects three more to enter Phase 1 this year, targeting 10 clinical-stage molecules by year-end 2026. These span FcRn follow-ups, IgA, IL-6, and other immune targets. The Halozyme collaboration was expanded to cover six targets total.
But building a pipeline from scratch takes years. Buying Forte gives argenx a shortcut into a completely different mechanism of action, one that doesn't overlap with FcRn at all.
Wall Street's Verdict: Smart Move, Steep Price
Analyst reactions landed in a familiar zone: "we like the strategy, but did you have to pay that much?"
RBC Capital Markets analyst Luca Issi said the acquisition wasn't surprising, partly because argenx had already built a strategic equity stake in Forte earlier this year. But he noted he was surprised argenx didn't wait for more data before pulling the trigger on a full buyout. After all, FB102 is still in early-stage trials.
Leerink's Thomas Smith was more bullish, arguing that argenx's commercial infrastructure makes it uniquely suited to develop FB102 across multiple autoimmune settings. TD Cowen, meanwhile, downgraded Forte to Hold (the stock is now basically pinned to the $77 deal price, so there's not much upside left for Forte shareholders to chase).
Barclays had actually initiated coverage on Forte with an Overweight rating and a $74 price target before the deal was announced, which suggests the market was already warming up to FB102's potential.
The Bigger Picture
This acquisition tells you something important about where biotech M&A is heading in 2026. Companies with blockbuster franchises aren't waiting for assets to de-risk through late-stage trials. They're buying early, paying premiums, and betting on mechanisms they believe can scale across multiple diseases.
argenx isn't becoming an acquirer-of-everything. This appears to be a targeted, staged approach: invest first, diligence the science, then move to full acquisition when the early data looks promising. It's more like dating before proposing than eloping after a first date.
The risk is obvious. FB102 is still early. Phase 1b data in vitiligo and celiac disease is encouraging, but plenty of drugs look great in small trials and stumble later. Paying $2.2 billion for Phase 1b assets is aggressive by any standard.
But argenx has the cash (no financing needed), the commercial machine (19,000 patients treated across three indications), and a clear strategic gap to fill. If FB102 works in even two or three of its target indications, this deal could look like a steal in hindsight.
And if it doesn't? Well, $2.2 billion is a lot of money to learn a lesson. But when you're pulling in $4.2 billion a year from a single franchise, you can afford to swing for the fences.
Deals & M&A5 min read
Pathos AI Just Spent $2.2 Billion to Prove It's Not Just Another AI Hype Machine
Pathos AI dropped $125 million upfront and committed to a deal worth up to $2.2 billion for a Chinese cancer drug, then inked a partnership with AstraZeneca in the same week. It's the biggest test yet of whether AI can actually pick winners in drug development.
